Get started
Author

Elaine Brinkworth

Mapping the human genetic architecture of COVID-19
2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Eugenia Abaleke, Mustafa Abbas, et al. · The Lancet · 533
PDF
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 493
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 369
Whole-genome sequencing reveals host factors underlying critical COVID-19
2022 · Athanasios Kousathanas, Erola Pairo-Castineira, et al. · Nature · 326
PDF
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
2022 · Obbina Abani, Ali Abbas, et al. · The Lancet · 324
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2021 · Obbina Abani, Ali Abbas, et al. · The Lancet · 290
GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 224
PDF
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · Obbina Abani, Ali Abbas, et al. · The Lancet · 129
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
2023 · Christina Kapizioni, Rofaida Desoki, et al. · Journal of Crohn s and Colitis · 123
PDF
A second update on mapping the human genetic architecture of COVID-19
2023 · The COVID-19 Host Genetics Initiative, Leadership, et al. · Nature · 118
PDF
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
2013 · S Holt, G Bertelli, et al. · British Journal of Cancer · 102
PDF
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
2022 · Simeng Lin, Nicholas A. Kennedy, et al. · Nature Communications · 96
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity
2021 · Chiara Fallerini, Nicola Picchiotti, et al. · Human Genetics · 37
PDF
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
2022 · Zhigang Liu, Kaixing Le, et al. · ˜The œLancet. Gastroenterology & hepatology · 36
Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
2023 · Ramesh Nadarajah, Peter Ludman, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 21
PDF
Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
2022 · Ramesh Nadarajah, Peter Ludman, et al. · European Heart Journal - Quality of Care and Clinical Outcomes · 20
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Stratified analyses refine association between TLR7 rare variants and severe COVID-19
2024 · Jannik Boos, Caspar I. van der Made, et al. · Human Genetics and Genomics Advances · 12
PDF
Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
2023 · Erola Pairo-Castineira, Konrad Rawlik, et al. · Nature · 9
PDF
P5-14-26: Results from a Prospective Clinical Study on the Impact of Oncotype DX on Adjuvant Treatment Decision Making in a Cohort of 142 UK Patients.
2011 · S Holt, G Bertelli, et al. · Cancer Research · 6
P196 Results from a prospective clinical study on the impact of Oncotype DX on adjuvant treatment decision and risk classification by Nottingham prognostic index (NPI) and recurrence score (RS)
2011 · S.D.H. Holt, G. Bertelli, et al. · The Breast · 6
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
Works count: 28
Citation count: 4,357
H-index: 19
I10-index: 21
Year
Topic
Type